Measurement of tissue factor activity in extracellular vesicles from human plasma samples.

biomarker extracellular vesicles plasma thrombosis tissue factor

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 25 09 2018
accepted: 13 10 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 19 1 2019
Statut: epublish

Résumé

Tissue factor (TF) is the cellular receptor for plasma factor (F) VII/FVIIa and triggers blood coagulation. Extracellular vesicles (EVs) are small membrane vesicles that are released from activated cells and tumor cells. Different cell types, including activated monocytes and tumors cells release TF-positive EVs into the circulation. We developed an assay to measure levels of TF activity in EVs isolated from human plasma samples. We and others have used this assay to demonstrate increased levels of EV TF activity in a variety of diseases associated with thrombosis, including cancer. These studies suggest that EV TF can be used as a biomarker of thrombotic risk. The strength of this laboratory assay is that it is relatively sensitive and specific. However, the limitations of the assay are that it is labor intensive and the coefficient of variation is too high for it to be used as a clinical assay.

Identifiants

pubmed: 30656275
doi: 10.1002/rth2.12165
pii: S2475-0379(22)01512-6
pmc: PMC6332748
doi:

Types de publication

Journal Article

Langues

eng

Pagination

44-48

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007149
Pays : United States

Références

J Thromb Haemost. 2012 Jul;10(7):1363-70
pubmed: 22520016
Circ Res. 2017 May 12;120(10):1632-1648
pubmed: 28495994
Thromb Res. 2014 May;133(5):799-803
pubmed: 24657035
J Thromb Haemost. 2007 Mar;5(3):520-7
pubmed: 17166244
J Clin Oncol. 2017 Apr 1;35(10):1128-1130
pubmed: 28029321
J Thromb Haemost. 2012 Jun;10(6):1185-8
pubmed: 22489893
Br J Cancer. 2016 Jul 26;115(3):332-8
pubmed: 27404454
J Thromb Haemost. 2006 Aug;4(8):1747-55
pubmed: 16879217
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
Blood. 2010 Jan 28;115(4):879-86
pubmed: 19861681
J Thromb Haemost. 2008 Nov;6(11):1983-5
pubmed: 18795992
Thromb Res. 2016 Mar;139:90-7
pubmed: 26916302
J Thromb Haemost. 2009 Aug;7(8):1421-3
pubmed: 19500241
Thromb Haemost. 2011 Jan;105(1):14-20
pubmed: 21057704
J Thromb Haemost. 2009 May;7(5):894-7
pubmed: 19220730
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1493-8
pubmed: 15860742
Res Pract Thromb Haemost. 2018 Nov 20;3(1):44-48
pubmed: 30656275
Semin Thromb Hemost. 2010 Nov;36(8):865-75
pubmed: 21049387
Biochem J. 1990 Jan 15;265(2):327-36
pubmed: 2302175
Gynecol Oncol. 2017 Jul;146(1):146-152
pubmed: 28501328
Thromb Res. 2012 Jan;129(1):80-5
pubmed: 21737126
PLoS One. 2018 Nov 9;13(11):e0207387
pubmed: 30412630
J Thromb Haemost. 2014 Nov;12(11):1932-4
pubmed: 25186801
J Thromb Haemost. 2013 Apr 2;:
pubmed: 23551930
Thromb Res. 2016 May;141:39-48
pubmed: 26967531

Auteurs

Yohei Hisada (Y)

Division of Hematology and Oncology, Thrombosis and Hemostasis Program Department of Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina.

Nigel Mackman (N)

Division of Hematology and Oncology, Thrombosis and Hemostasis Program Department of Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina.
Department of Pathology and Laboratory Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina.

Classifications MeSH